These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29438365)

  • 1. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
    Viala M; Vinches M; Alexandre M; Mollevi C; Durigova A; Hayaoui N; Homicsko K; Cuenant A; Gongora C; Gianni L; Tosi D
    Br J Cancer; 2018 Mar; 118(5):679-697. PubMed ID: 29438365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
    Tosi D; Laghzali Y; Vinches M; Alexandre M; Homicsko K; Fasolo A; Del Conte G; Durigova A; Hayaoui N; Gourgou S; Gianni L; Mollevi C
    J Clin Oncol; 2015 Jul; 33(19):2158-65. PubMed ID: 26014300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of the recommended phase 2 dose of molecular targeted agents.
    Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
    Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
    Nikanjam M; Liu S; Kurzrock R
    Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
    Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
    Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda.
    Luo J; Nishikawa G; Prasad V
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2303-2311. PubMed ID: 31396700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
    Mittapalli RK; Yin D; Beaupre D; Palaparthy R
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):23-30. PubMed ID: 33237334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
    Salgia R; Patel P; Bothos J; Yu W; Eppler S; Hegde P; Bai S; Kaur S; Nijem I; Catenacci DV; Peterson A; Ratain MJ; Polite B; Mehnert JM; Moss RA
    Clin Cancer Res; 2014 Mar; 20(6):1666-75. PubMed ID: 24493831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.
    Jardim DL; Hess KR; Lorusso P; Kurzrock R; Hong DS
    Clin Cancer Res; 2014 Jan; 20(2):281-8. PubMed ID: 24190980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in Oncology.
    Chen C; Fan X; Zhang L; Xu P; Zou H; Zhao X; Gupta M; Feng YS; Xu XS; Yan X
    Clin Pharmacokinet; 2023 May; 62(5):705-713. PubMed ID: 36930421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
    Penel N; Duhamel A; Adenis A; Devos P; Isambert N; Clisant S; Bonneterre J
    Invest New Drugs; 2012 Apr; 30(2):653-61. PubMed ID: 21049280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing time to determination of the recommended phase 2 dose in phase 1 clinical trials.
    Caldwell S; Sima C; Jameson G; Fleck S; Weiss GJ
    Am J Clin Oncol; 2013 Apr; 36(2):146-50. PubMed ID: 22314002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies.
    Taylor RP; Lindorfer MA
    Mol Pharmacol; 2014 Nov; 86(5):485-91. PubMed ID: 24944188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
    Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
    Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology.
    Li TR; Chatterjee M; Lala M; Abraham AK; Freshwater T; Jain L; Sinha V; de Alwis DP; Mayawala K
    Clin Pharmacol Ther; 2021 Jul; 110(1):200-209. PubMed ID: 33462831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.